ECSP22014379A - Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones - Google Patents

Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones

Info

Publication number
ECSP22014379A
ECSP22014379A ECSENADI202214379A ECDI202214379A ECSP22014379A EC SP22014379 A ECSP22014379 A EC SP22014379A EC SENADI202214379 A ECSENADI202214379 A EC SENADI202214379A EC DI202214379 A ECDI202214379 A EC DI202214379A EC SP22014379 A ECSP22014379 A EC SP22014379A
Authority
EC
Ecuador
Prior art keywords
formulations
compounds
composition
compound
disclosed
Prior art date
Application number
ECSENADI202214379A
Other languages
English (en)
Inventor
lu Chou
Somasekhar Bhamidipati
Vanessa Taylor
Zhushou Luo
Dazhong Fan
Ihab Darwish
Matt Duan
Yan Chen
Simon Shaw
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of ECSP22014379A publication Critical patent/ECSP22014379A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se desvelan realizaciones de un compuesto de pirazol de acuerdo con la fórmula (I). También se desvelan composiciones que comprenden el compuesto, y un método para preparar la composición. La composición puede comprender un vehículo, tal como un polímero y/o la composición puede ser una formulación secada por pulverización. También se desvela un método para usar el compuesto y/o composición. El compuesto y/o composición pueden ser útiles para inhibir una proteína IRAK y/o para mejorar, tratar y/o prevenir una enfermedad o afección asociada a IRAK en un sujeto.
ECSENADI202214379A 2019-08-30 2022-02-23 Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones ECSP22014379A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962894547P 2019-08-30 2019-08-30

Publications (1)

Publication Number Publication Date
ECSP22014379A true ECSP22014379A (es) 2022-05-31

Family

ID=72473975

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202214379A ECSP22014379A (es) 2019-08-30 2022-02-23 Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones

Country Status (22)

Country Link
US (3) US11370787B2 (es)
EP (1) EP4003990A1 (es)
JP (1) JP2022545542A (es)
KR (1) KR20220054626A (es)
CN (2) CN121159524A (es)
AR (1) AR119857A1 (es)
AU (1) AU2020335903A1 (es)
BR (1) BR112022003564A2 (es)
CA (1) CA3152264A1 (es)
CO (1) CO2022002993A2 (es)
CR (1) CR20220085A (es)
DO (1) DOP2022000047A (es)
EC (1) ECSP22014379A (es)
IL (1) IL290882B1 (es)
JO (1) JOP20220050A1 (es)
MX (1) MX2022002292A (es)
PE (1) PE20220970A1 (es)
PH (1) PH12022550466A1 (es)
PY (1) PY2049213A (es)
SA (1) SA522431791B1 (es)
TW (1) TWI870449B (es)
WO (1) WO2021041898A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020335903A1 (en) * 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
JP2024534919A (ja) * 2021-09-08 2024-09-26 ライジェル ファーマシューティカルズ， インコーポレイテッド 呼吸器ウイルスによる感染症に関連するサイトカイン放出関連状態を治療するためのｉｒａｋ阻害剤
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
CN119950825B (zh) * 2025-03-13 2025-07-22 北京工业大学 基于压电驱动的自适应释药电纺覆膜气管支架的制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
WO2010121243A1 (en) 2009-04-17 2010-10-21 University Of Arizona Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
EP2243481A1 (en) 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
SG184475A1 (en) 2010-04-07 2012-11-29 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MX344521B (es) 2010-11-19 2016-12-19 Ligand Pharm Inc Aminas heterociclicas y sus usos.
CA2819378A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
US8703941B2 (en) 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
EP2674423A4 (en) 2011-02-09 2014-07-30 Nissan Chemical Ind Ltd PYRAZONE DERIVATIVE AND PESTICIDES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
US8614206B2 (en) 2011-09-27 2013-12-24 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
BR112014017021A8 (pt) 2012-01-10 2017-07-04 Nimbus Iris Inc inibidores de irak e usos dos mesmos
JP6666147B2 (ja) 2012-09-26 2020-03-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 環状エーテルピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
KR102293952B1 (ko) 2013-02-07 2021-08-26 메르크 파텐트 게엠베하 피리다지논 아미드 유도체
CN105008371B (zh) 2013-02-07 2018-09-18 默克专利股份公司 大环哒嗪酮衍生物
ES2728403T3 (es) 2014-01-09 2019-10-24 Merck Patent Gmbh Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK
NZ730728A (en) 2014-11-20 2022-04-29 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
SG11201707752SA (en) 2015-04-22 2017-11-29 Rigel Pharmaceuticals Inc Pyrazole compounds and method for making and using the compounds
DK3532470T3 (da) * 2016-10-26 2023-02-20 Rigel Pharmaceuticals Inc Oxazolderivater til anvendelse som irak-hæmmere og fremgangsmåde til fremstilling deraf
AU2020335903A1 (en) * 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Also Published As

Publication number Publication date
PH12022550466A1 (en) 2023-03-06
IL290882A (en) 2022-04-01
US20230399326A1 (en) 2023-12-14
CN121159524A (zh) 2025-12-19
JOP20220050A1 (ar) 2023-01-30
US12441723B2 (en) 2025-10-14
AR119857A1 (es) 2022-01-19
TW202122393A (zh) 2021-06-16
CN114364674B (zh) 2025-10-03
PY2049213A (es) 2021-05-05
TWI870449B (zh) 2025-01-21
JP2022545542A (ja) 2022-10-27
BR112022003564A2 (pt) 2022-05-17
WO2021041898A1 (en) 2021-03-04
CR20220085A (es) 2022-04-19
EP4003990A1 (en) 2022-06-01
CO2022002993A2 (es) 2022-04-19
DOP2022000047A (es) 2022-04-29
KR20220054626A (ko) 2022-05-03
US11370787B2 (en) 2022-06-28
CN114364674A (zh) 2022-04-15
SA522431791B1 (ar) 2025-04-14
IL290882B1 (en) 2025-11-01
AU2020335903A1 (en) 2022-03-24
US20210061798A1 (en) 2021-03-04
CA3152264A1 (en) 2021-03-04
US20220306620A1 (en) 2022-09-29
MX2022002292A (es) 2022-06-02
PE20220970A1 (es) 2022-06-10

Similar Documents

Publication Publication Date Title
DOP2022000047A (es) Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2019000986A1 (es) 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds).
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
PE20171517A1 (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac 8
MX2022005509A (es) Compuestos inhibidores de rip1 heterociclicos.
UY29277A1 (es) Derivados de benzamidas (4(4-(1-isopropil-2-metil-1h-imidazol-5-il)-pirimidin-2-il)amino)sustitudas, composiciones que los contienen, procedimiento de preparación y aplicaciones
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
PH12016501932A1 (en) Amido-substituted azole compounds
UY36074A (es) ?derivados de dihidropirrolopirimidina? .
CO2025018165A2 (es) Agonistas de trem2
ECSP066997A (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
BR112021014640A8 (pt) Sais de sulcardina
CL2022000320A1 (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones
BR112017028185A2 (pt) composições farmacêuticas sólidas para tratar hcv
BR112022004777A2 (pt) Composição de micela de estimulação imunológica
BR112018000982A2 (pt) composições farmacêuticas sólidas para tratar hcv
CO2020004599A2 (es) Inhibidor de mpges-1 para el tratamiento de dolor de osteoartritis